Porphyria cutanea tarda (PCT) is a condition where your skin becomes extremely fragile and blisters easily in sun-exposed areas. It’s the most common type of porphyria, affecting roughly 10 in every 100,000 people worldwide. The underlying problem is a shortage of a specific enzyme in the liver that helps process heme, the iron-containing molecule in your red blood cells. When this enzyme doesn’t work properly, byproducts called porphyrins build up in your body, travel to your skin, and react with sunlight to cause damage.
What Happens Inside the Body
Your liver uses an enzyme called uroporphyrinogen decarboxylase (UROD) as part of the multi-step process of making heme. In PCT, UROD activity drops low enough that intermediate compounds, particularly uroporphyrin, accumulate in liver cells and spill into the bloodstream. These porphyrins eventually deposit in the skin, where they absorb light energy and generate reactive molecules that injure surrounding tissue. The result is skin that tears, blisters, and scars with minimal provocation.
Iron plays a central role in driving this process. Excess iron in the liver increases the production of reactive oxygen species, which accelerate porphyrin accumulation in three ways: they speed the conversion of porphyrin precursors into their final (and problematic) forms, they help create a chemical inhibitor that further suppresses UROD activity, and they boost the supply of raw materials feeding into the porphyrin pathway. This is why conditions that load iron into the liver are so closely linked to PCT.
Sporadic vs. Familial Types
About 80% of PCT cases are “sporadic” (sometimes called Type I), meaning there’s no inherited mutation in the UROD gene. Instead, a combination of environmental and metabolic stressors suppresses the enzyme enough to trigger symptoms, typically in middle-aged adults.
The remaining cases are familial (Type II), caused by an inherited mutation in one copy of the UROD gene. Over 140 different mutations have been identified so far. Inheriting one mutated copy doesn’t guarantee you’ll develop PCT, but it lowers the threshold, so fewer outside triggers are needed to push UROD activity into the danger zone. When both copies of the gene are affected, a much more severe condition called hepatoerythropoietic porphyria can appear in early childhood.
Common Triggers
Most people with PCT can point to one or more factors that tipped their enzyme activity over the edge. The major triggers are:
- Excess alcohol intake: Alcohol increases oxidative stress in the liver and directly promotes porphyrin overproduction.
- Iron overload: Hereditary hemochromatosis gene variants (HFE mutations) are common in PCT patients, causing the body to absorb and store too much iron.
- Hepatitis C: Chronic infection both increases oxidative stress and suppresses hepcidin, a hormone that regulates iron absorption, leading to further iron accumulation.
- Estrogen therapy: Oral contraceptives and hormone replacement therapy can trigger or worsen PCT through the same oxidative pathways.
- Smoking: Cigarette smoke activates liver enzymes that contribute to UROD inhibition.
- HIV infection: Less commonly, HIV is associated with PCT onset.
In most patients, several of these factors overlap. Someone with a mild HFE mutation who also drinks heavily and has hepatitis C, for example, faces a much higher risk than someone with just one trigger.
What the Skin Looks Like
The hallmark of PCT is skin that blisters and tears on areas regularly exposed to sunlight: the backs of the hands, the forearms, the face, the neck, and sometimes the tops of the feet. Even minor bumps or friction can split the skin open. The blisters range from small vesicles to larger fluid-filled bullae that rupture easily and heal slowly.
Over time, repeated blistering leaves behind a mix of lighter and darker scars along with milia, tiny yellowish-white bumps filled with keratin. Some people develop thickened, tight patches of scarring that resemble scleroderma, a phenomenon sometimes called pseudoscleroderma. Women may notice increased facial hair along the cheeks, temples, and forearms. Diffuse hair loss from scarring on the scalp is also possible, and some patients develop blue to purplish-brown discoloration around the eyes and cheekbones.
How PCT Is Diagnosed
Diagnosis relies heavily on urine and blood tests measuring porphyrin levels. A urine porphyrin profile in PCT typically shows elevated uroporphyrin and heptacarboxylporphyrin, a pattern that helps distinguish it from other types of porphyria. A stool porphyrin test can further narrow down the subtype.
To determine whether someone has the familial form, a blood test measuring UROD enzyme activity in red blood cells can be helpful. Decreased activity points toward Type II (familial) PCT. Genetic testing for UROD mutations can confirm this. Most patients will also be tested for hepatitis C, HIV, iron levels, and HFE gene mutations to identify treatable triggers.
Treatment Options
Treatment targets the iron overload and porphyrin buildup that drive the disease. The two main approaches are equally effective, and the choice often depends on whether the patient can tolerate blood removal.
Phlebotomy
Therapeutic phlebotomy, essentially the same as donating blood, is the traditional first-line treatment. Blood is drawn on a regular schedule, typically weekly or every two weeks, with each session removing a controlled volume based on body weight. The goal is to bring serum ferritin (a marker of iron stores) below 50 mcg/L. Most people reach this target after four to five sessions. As iron stores drop, UROD function gradually recovers, porphyrin levels normalize, and skin symptoms improve over the following weeks to months.
Low-Dose Antimalarials
For patients who can’t undergo regular phlebotomy (due to anemia, for instance), low-dose hydroxychloroquine is an effective alternative. The standard regimen is 100 to 200 mg taken twice weekly. At these low doses, the medication mobilizes porphyrins from the liver and promotes their excretion in urine. Higher doses of antimalarials can cause a temporary but dramatic spike in porphyrin release that damages the liver, which is why the low-dose approach matters. Clinical trials have shown this regimen works as well as phlebotomy for achieving remission.
Addressing Underlying Triggers
Regardless of which primary treatment is used, managing triggers is essential to prevent relapse. That means treating hepatitis C if present, stopping or reducing alcohol intake, discontinuing estrogen therapy when possible, and quitting smoking. Many patients who address their triggers and complete treatment go into long-term remission, though PCT can return if triggers resurface.
Protecting Your Skin
Sun protection is critical both during active disease and afterward. The challenge with PCT is that porphyrins react not just to ultraviolet light but also to visible light, which standard sunscreens don’t fully block. Physical (mineral) sunscreens containing zinc oxide, titanium dioxide, or iron oxide offer better protection in the visible light range than chemical-only sunscreens. Tinted products and foundation-type formulations tend to perform better than clear sunscreens for blocking visible wavelengths, because the pigments themselves act as a physical barrier.
Covering exposed skin with clothing, wearing broad-brimmed hats, and avoiding peak sun hours all reduce the chance of triggering new blisters. These measures remain important even after porphyrin levels normalize, since relapses are possible.
Liver Health and Long-Term Outlook
Because PCT is fundamentally a liver disease, long-term liver health deserves attention. Many PCT patients already have underlying liver conditions, whether from hepatitis C, alcohol use, or iron overload. The combination of these factors can lead to fibrosis or cirrhosis over time.
There is a small but real association between PCT and liver cancer. In one long-term follow-up study, hepatocellular carcinoma developed at a rate of about 0.26% per patient-year, with the risk appearing to be driven largely by coexisting hepatitis C or advanced liver scarring rather than PCT alone. Patients with these additional risk factors are typically monitored with liver ultrasound and blood tests every six months to catch any problems early.
For most people, PCT is a treatable and manageable condition. Once iron stores are reduced, triggers are addressed, and porphyrin levels return to normal, the skin heals and symptoms resolve. Staying aware of your triggers and maintaining follow-up gives you the best chance of staying in remission long-term.